Search
Search Results
##search.searchResults.foundPlural##
-
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
3916PDF: 1097HTML: 444 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1381PDF: 1306HTML: 100 -
Severe autoimmune hemolytic anemia in Covid-19 infection Autoimmune hemolytic anemia in Covid-19
3197PDF: 1580HTML: 259 -
Takayasu Arteritis Initially Mimicking Infective Endocarditis
1267PDF: 601HTML: 1096 -
COAGULOPATHY IN BETA-THALASSEMIA: CURRENT UNDERSTANDING AND FUTURE PERSPECTIVES
1110PDF: 486HTML: 8165 -
FASTING PLASMA GLUCOSE LEVELS WITHIN THE HIGH NORMAL RANGE ARE ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF FUTURE DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β THALASSEMIA: A DECADE-LONG MULTICENTER RETROSPECTIVE ANALYSIS Higher normal fasting plasma glucose and glucose dysregulation in β- thalassemia
631PDF: 240Html: 32 -
COULD PLASMA GLUCOSE (PG) INCREMENT (PG %) EXPAND THE CLINICAL WEIGHT OF OGTT? PRELIMINARY FINDINGS IN 19 TDT PATIENTS (Β-TDT) WITH NORMAL GLUCOSE TOLERANCE Plasma glucose (PG) increment (PG %) and pancretic β-cell dysfunction in thalassemia
715PDF: 495HTML: 42 -
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA
2049PDF: 1863HTML: 347 -
CAN WE PREDICT INCIPIENT DIABETES MELLITUS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (β-TDT) REFERRED WITH A HISTORY OF PREDIABETES? Risk factors for incipient diabetes in thalassemia
1048PDF: 1337HTML: 106 -
MALARIA AND HIV IN ADULTS: When The Parasite runs into The Virus
2695PDF: 1008HTML: 2265 -
HIV INFECTION, ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR RISK
1827PDF: 799HTML: 3600 -
Tacrolimus Associated Posterior Reversible Encephalopathy Syndrome – A Case Series and Review
3547PDF: 1491HTML: 4398CoverLetter: 184Figure1: 194 -
ROLE OF CYTOKINES AS MOLECULAR MARKER OF DENGUE SEVERITY
3173PDF: 1151HTML: 394 -
Improvement of liver involvement in familial Mediterranean fever after introduction of canakinumab: a case report Liver involvement in familial Mediterranean fever
1312PDF: 912HTML: 294 -
Simultaneous dual pathology in lymph node
1650PDF: 693HTML: 7695Simultaneous dual pathology in lymph node: 174Simultaneous dual pathology in lymph node: 171Simultaneous dual pathology in lymph node: 149Simultaneous dual pathology in lymph node: 188Simultaneous dual pathology in lymph node: 173 -
IMMUNE THROMBOCYTOPENIA ONSET AND RELAPSE DURING THE COVID19 PANDEMIC. A MONOCENTER STUDY. ITP and COVID19 infection and vaccination
1429PDF: 805HTML: 315 -
A rare case of multidrug resistant Leclercia adecarboxylata catheter-related bloodstream infection and an updated brief literature review Leclercia adecarboxylata catheter-related bloodstream infection.
828PDF: 552HTML: 162 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3553PDF: 2413HTML: 1465 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1532PDF: 942HTML: 222 -
SIMPLE PERIPHERAL BLOOD SMEAR FINDINGS OF COVID-19 PATIENTS PROVIDE INFORMATION ABOUT THE SEVERITY OF THE DISEASE AND THE DURATION OF HOSPITAL STAY. Peripheral blood smear and COVID-19 severity.
3268PDF: 1095HTML: 438 -
EVALUATION OF THE PLASMA MICRO RNA EXPRESSION LEVELS IN SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
1389PDF: 689HTML: 1089Untitled: 182Untitled: 149Untitled: 131Untitled: 152Untitled: 161







